Cardiovascular

Latest News

AJMC
Impact of Delayed Adoption of Novel Atrial Fibrillation Treatments

December 11th 2024

Using direct oral anticoagulants as a case study, the authors examined how delayed adoption of novel treatments could impact patient health outcomes and cost.

Highlights from ASPC Congress 2024 | Image Credit: venngage.com
ICYMI: Highlights From ASPC Congress 2024

December 9th 2024

EKG heartbeat line | Image Credit: Jiva Core - stock.adobe.com
Acoramidis Sustains Benefits in Patients With ATTR-CM in Open-Label Extension Study

December 6th 2024

Atrial fibrillation | Image credit: ibreakstock - stock.adobe.com
Lifestyle Changes Ease AFib Symptoms but Don't Lower Burden vs Standard Care

December 5th 2024

FDA headquarters | Image Credit: Grandbrothers - stock.adobe.com
FDA Approves Acoramidis for ATTR-CM

November 25th 2024

Advancements in Population Health Strategies for Cardiovascular Risk Management

Experts discuss how lipoproteins drive atherosclerotic heart disease, review the different guidelines and recommendations on Lp(a) testing, and insights from clinical trials.

Hands holding a heart with a heartbeat on it and the words AJMC Insights
Continuing Medical Education
View All
December 14th 2024

Evidence-Based Guidelines Point to Leap in Care for Hypertrophic Cardiomyopathy

December 11, 2024 | 1:00 PM & 8:00 PM ET
December 14th 2024

Advances and Best Practices for Managed Care Pharmacists in the Treatment of Heart Failure with Preserved Ejection Fraction

1.0 Credits / Cardiology
December 14th 2024

Exploring Transthyretin-Mediated Amyloidosis and Its Phenotypes: A Comprehensive Approach to Patient Treatment

1.5 Credits / Cardiology, Neurology, Rare Diseases
December 14th 2024

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

More News

Site Logo
April 13th 2021

Two Steps Forward, One Step Back: 50 Years of Societal Value From LDL-C–Lowering Therapies

Joanna P. MacEwan, PhD Lauren M. Zhao, BA Katie Everson, MS Larry Liu, MD, PhD Dominik Lautsch, PhD Fang Sun, MD, PhD Darius N. Lakdawalla, PhD
Low-density lipoprotein cholesterol (LDL-C)–lowering therapies have yielded significant value to society through reduced costs for both fatal and nonfatal cardiovascular disease events. The vast majority of this value has accrued to patients.
Site Logo
April 8th 2021

Clinical and Economic Outcomes of a Collaborative Cardiology Care Program

Felix Sebastian Wicke, MD, MSc Bianka Ditscheid, PhD Thorben Breitkreuz, MSc Anastasiya Glushan, BSc Thomas Lehmann, PhD Kateryna Karimova, PhD, MSc Olga Anastasia Sawicki, MD, MSc Monique Vogel, MD Antje Freytag, PhD Martin Beyer, MSc
Patients with chronic cardiac conditions benefited from a health care program that strengthened collaboration between general practitioners and cardiology specialists in Baden-Wuerttemberg, Germany.
Early Intervention in Younger Patients With CAD Benefits Long-Term Prognosis
December 31st 2020

Early Intervention in Younger Patients With CAD Benefits Long-Term Prognosis

Samantha DiGrande
Premature coronary artery disease (CAD) is an aggressive disease with a high rate of ischemic recurrences and premature death, researchers said.
Top 5 Most-Read Conference Stories of 2020
December 29th 2020

Top 5 Most-Read Conference Stories of 2020

Skylar Jeremias
The top 5 most-read conference stories of 2020 on AJMC.com included stories about study results on the impact that new therapies are having on cardiovascular and renal health.
Bleeding After DAPT Found to Be an Independent Predictor of Cardiovascular Events
December 28th 2020

Bleeding After DAPT Found to Be an Independent Predictor of Cardiovascular Events

Samantha DiGrande
A recent study sought to estimate the incidence of clinical events such as bleeding, myocardial infarction, and all-cause mortality in patients with acute myocardial infarction and chronic coronary syndrome who received dual antiplatelet therapy (DAPT) after coronary stenting.
ACC/AHA Clarify When AF Patients With Mitral Stenosis Should—And Should Not—Take DOACs
December 24th 2020

ACC/AHA Clarify When AF Patients With Mitral Stenosis Should—And Should Not—Take DOACs

Larry Hanover
The distinction between valvular and nonvalvular atrial fibrillation (AF) has been a persistent point of confusion for clinicians.
New ACC Pathway in Atrial Fibrillation Calls for Limiting Aspirin
December 22nd 2020

New ACC Pathway in Atrial Fibrillation Calls for Limiting Aspirin

Larry Hanover
The American College of Cardiology provides new guidance on the best therapy to prevent blood clots for patients with atherosclerotic cardiovascular disease who also have atrial fibrillation or venous thromboembolism and require an anticoagulant.
Study Finds Vascepa Reduces Patient-Reported COVID-19 Symptoms
December 19th 2020

Study Finds Vascepa Reduces Patient-Reported COVID-19 Symptoms

Samantha DiGrande
Giving patients icosapent ethyl, or Vascepa, led to a 52% reduction of the total patient-reported symptom outcome prevalence score as compared with a 24% decline for outpatients who received usual care.
Cardiovascular Complications in Patients With Diabetes Drop in South Korea, Study Finds
December 18th 2020

Cardiovascular Complications in Patients With Diabetes Drop in South Korea, Study Finds

Samantha DiGrande
There was a significant decrease in the rates of cardiovascular complications and mortality in adults with diabetes in South Korea, but other conditions increased.
Several beers
December 12th 2020

Heavy Drinking Increases Risk of AF-Related Adverse Events

Samantha DiGrande
Despite heavy alcohol consumption being linked to increased incidence of atrial fibrillation (AF) and bleeding in patients with the condition, recommendations to control heavy drinking among this patient population are lacking.
Sad child
December 10th 2020

Adverse Childhood Experiences Associated With CVD Later in Life

Samantha DiGrande
Childhood abuse, household dysfunction, and neglect were linked in a recent study to an increased risk of developing cardiovascular disease in adulthood.
Oral anticoagulants
December 5th 2020

Oral Anticoagulants Touted as Having “Excellent Efficacy” in Postoperative Atrial Fibrillation

Samantha DiGrande
A recent prospective, observational study investigated the use of direct oral anticoagulants for use in patients with postoperative atrial fibrillation and found favorable safety and efficacy results.
Population Management Tool Reduces Adverse Events of DOACs
December 3rd 2020

Population Management Tool Reduces Adverse Events of DOACs

Samantha DiGrande
The use of a population health management tool may reduce adverse events that may arise from the inappropriate prescribing of direct-acting oral anticoagulants (DOACs).
Carotid Artery Lipid Core Associated With CVD, Independent of Artery Wall Thickness
November 27th 2020

Carotid Artery Lipid Core Associated With CVD, Independent of Artery Wall Thickness

Samantha DiGrande
It remains unclear whether measures of magnetic resonance imaging plaque characteristics are associated with cardiovascular disease events independent of plaque burden at the population level.
Association Between Clogged Arteries and Body Size Phenotype? Study Finds, “It Varies”
November 25th 2020

Association Between Clogged Arteries and Body Size Phenotype? Study Finds, “It Varies”

Samantha DiGrande
Cardiac graphic
November 17th 2020

Study Highlights Finerenone Benefits in CV Outcomes for Patients With CKD

Allison Inserro
Finerenone may represent an important step forward to reducing cardiac illness and death in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), the study said.
Lincoff
November 15th 2020

Fish Oil Debate Continues as Study Finds No Risk Reduction From Omega-3 Combo

Mary Caffrey
The investigator of the STRENGTH study says findings raise questions about the landmark REDUCE-IT trial, but other evidence suggests the drugs involved are different.
Site Logo
November 10th 2020

AHA Telemetry Guidelines Improve Telemetry Utilization in the Inpatient Setting

Sima S. Pendharkar, MD, MPH Ibrahim B. Barry, MD, MPH Saikrishna Patibandla, MD, MS Tiffany I. Leung, MD, MPH Amol Gupta, MBBS Aung Naing Lin, MD James A. Gasperino, MD, PhD, MPH
Using Plan-Do-Study-Act cycles, the studied intervention reduced hospital inpatient telemetry time by 51.25% while increasing American Heart Association (AHA) guideline–based usage.
Site Logo
November 10th 2020

Telemetry: Appropriateness of Initial Assignment and Duration in Nonintensive Setting

Rohit Chaudhary, MIS Thomas Kingsley, MD Sauradeep Sarkar, MD Joseph Carrington, DO Galo M. Sanchez Palacios, MD Tushar Sharma, MD Jalaj Garg, MD Rahul Chaudhary, MD, MBA
The authors report overutilization of telemetry monitoring in a community setting, increasing the cost of health care and potential harm to patients with unnecessary interventions.
Site Logo
October 19th 2020

Social Determinants of Health Score: Does It Help Identify Those at Higher Cardiovascular Risk?

Ana Palacio, MD, MPH Ruaa Mansi, MD, MPH David Seo, MD Maritza Suarez, MD Sylvia Garay, MD Heidy Medina, MPH Fei Tang, PhD Leonardo Tamariz, MD, MPH
Calculating a social score is feasible and it predicts cardiovascular outcomes. In order to do this, institutions have to collect social determinants of health.
Better Strategies to Reduce Cardiovascular Events
September 16th 2020

Better Strategies to Reduce Cardiovascular Events

Clinical Pathways for Cardiovascular Disease Management
September 16th 2020

Clinical Pathways for Cardiovascular Disease Management

CVD: Cost-Effectiveness Data and Treatment Selection
September 16th 2020

CVD: Cost-Effectiveness Data and Treatment Selection

Cost-Effectiveness Data and Pricing of Icosapent Ethyl
September 16th 2020

Cost-Effectiveness Data and Pricing of Icosapent Ethyl

CV Risk Reduction and Coverage of Therapies
September 16th 2020

CV Risk Reduction and Coverage of Therapies

Cardiovascular Disease Treatment Decisions and Cost
September 16th 2020

Cardiovascular Disease Treatment Decisions and Cost

Cost-Effectiveness and Cardiovascular Risk
September 16th 2020

Cost-Effectiveness and Cardiovascular Risk

Implications for Treating Patients With Icosapent Ethyl
September 16th 2020

Implications for Treating Patients With Icosapent Ethyl

Coronary Plaque Regression and CV Risk
September 16th 2020

Coronary Plaque Regression and CV Risk

Interim Analysis of EVAPORATE
September 16th 2020

Interim Analysis of EVAPORATE

<123456789
...
22>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo